Deep Medicine Acquisition Corp. Rights
DMAQR
DMAQR was delisted on the 31st of January, 2024.
33 hedge funds and large institutions have $3.2M invested in Deep Medicine Acquisition Corp. Rights in 2021 Q4 according to their latest regulatory filings, with 33 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
+$474K |
| 2 |
CAC
Cowen and Company
New York
|
+$342K |
| 3 |
OCAM
Owl Creek Asset Management
New York
|
+$237K |
| 4 |
YCM
Yakira Capital Management
Westport,
Connecticut
|
+$237K |
| 5 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$206K |
Top Sellers
DMAQR Hedge Fund Activity: Q4 2021 in Review
33 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Deep Medicine Acquisition Corp. Rights (DMAQR) for Q4 2021, worth a combined $3.2M.
Buyers outnumbered sellers: 33 funds opened new DMAQR positions and 0 closed out — a net gain of 33 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Mangrove Partners, opening a new position worth an estimated $474K.
- 33 institutional investors held Deep Medicine Acquisition Corp. Rights (DMAQR) as of Q4 2021, up from 0 in Q3 2021.
- Funds reported $3.2M of Deep Medicine Acquisition Corp. Rights stock for Q4 2021.
- 33 funds opened new Deep Medicine Acquisition Corp. Rights positions in Q4 2021 and 0 closed out, a net change of +33 holders.
- The largest Deep Medicine Acquisition Corp. Rights buyer in Q4 2021 was Mangrove Partners, an estimated $474K added.
Based on aggregated 13F filings for Q4 2021.